Sio Capital Management LLC Has Raised Its Stake in Sage Therapeutics INC (Put) (SAGE) by $8.08 Million

March 14, 2018 - By Migdalia James

Investors sentiment increased to 1.21 in Q3 2017. Its up 0.23, from 0.98 in 2017Q2. It is positive, as 33 investors sold SAGE shares while 43 reduced holdings. 28 funds opened positions while 64 raised stakes. 38.55 million shares or 3.62% more from 37.20 million shares in 2017Q2 were reported. Td Asset Management Inc holds 0.01% or 83,918 shares. Tiaa Cref Inv Limited Liability Company stated it has 120,514 shares or 0.01% of all its holdings. Strs Ohio holds 0.02% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 69,900 shares. Jane Street Grp Ltd Com has invested 0% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Parametric Portfolio Assoc Limited Liability holds 21,697 shares or 0% of its portfolio. State Board Of Administration Of Florida Retirement invested in 16,852 shares or 0% of the stock. Canada Pension Plan Inv Board holds 0% or 800 shares. Citigroup Inc has 39,026 shares. 36,874 were accumulated by Alps Advsr. 33,334 are held by State Of Wisconsin Inv Board. Schwab Charles Mgmt Inc owns 0.01% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 151,026 shares. Oak Ridge reported 1.86% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Paloma Mgmt has invested 0% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Bessemer Grp Inc holds 0% or 2,263 shares. Great Lakes Advsrs Ltd Liability Corp reported 3,853 shares.

Since December 14, 2017, it had 0 insider buys, and 3 sales for $27.36 million activity. 58,139 shares were sold by PAUL STEVEN M, worth $10.00M on Tuesday, March 6. Kanes Stephen had sold 44,000 shares worth $7.80M on Wednesday, January 10.

Sio Capital Management Llc increased its stake in Sage Therapeutics Inc (Put) (SAGE) by 217.33% based on its latest 2017Q3 regulatory filing with the SEC. Sio Capital Management Llc bought 130,400 shares as the company’s stock rose 0.86% with the market. The institutional investor held 190,400 shares of the health care company at the end of 2017Q3, valued at $11.86 million, up from 60,000 at the end of the previous reported quarter. Sio Capital Management Llc who had been investing in Sage Therapeutics Inc (Put) for a number of months, seems to be bullish on the $7.96 billion market cap company. The stock decreased 0.05% or $0.08 during the last trading session, reaching $173.83. About 194,088 shares traded. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 116.45% since March 14, 2017 and is uptrending. It has outperformed by 99.75% the S&P500.

Sio Capital Management Llc, which manages about $116.75M and $192.73M US Long portfolio, decreased its stake in Advanced Accelerator Applications Sa by 55,941 shares to 52,582 shares, valued at $3.56M in 2017Q3, according to the filing.

More news for Sage Therapeutics, Inc. (NASDAQ:SAGE) were recently published by:, which released: “Sage Therapeutics Announces Fourth Quarter and Full Year 2017 Financial …” on February 22, 2018.‘s article titled: “Morgan Stanley Gets Wise On Sage Therapeutics, Initiates With A Buy” and published on February 26, 2018 is yet another important article.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Ratings Coverage

Among 18 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 16 have Buy rating, 0 Sell and 2 Hold. Therefore 89% are positive. SAGE Therapeutics had 55 analyst reports since September 3, 2015 according to SRatingsIntel. As per Thursday, November 2, the company rating was maintained by Stifel Nicolaus. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) earned “Buy” rating by Leerink Swann on Thursday, September 3. The firm has “Buy” rating by Canaccord Genuity given on Tuesday, September 12. The firm earned “Buy” rating on Thursday, September 3 by JP Morgan. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) has “Buy” rating given on Tuesday, September 12 by Needham. The stock has “Buy” rating by Leerink Swann on Thursday, December 7. RBC Capital Markets maintained it with “Buy” rating and $145.0 target in Thursday, November 9 report. The stock has “Buy” rating by RBC Capital Markets on Thursday, February 22. The stock has “Buy” rating by Cowen & Co on Tuesday, September 5. As per Friday, August 4, the company rating was maintained by H.C. Wainwright.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.